Arcutis announces positive topline data from phase II trial of topical roflumilast foam 0.3% as a potential treatment for seborrheic dermatitis

Study (n=226) reports roflumilast foam administered once daily demonstrated statistically significant improvement compared to a matching vehicle foam in primary endpoint of Investigator Global Assessment success rate ('clear' or 'almost clear') at week 8 (73.8 vs 40.9%; p<0.0001)

Biospace Inc.